S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
"We will NEVER sell out to China!" (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
"We will NEVER sell out to China!" (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
"We will NEVER sell out to China!" (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
"We will NEVER sell out to China!" (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
"We will NEVER sell out to China!" (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
"We will NEVER sell out to China!" (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
"We will NEVER sell out to China!" (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
"We will NEVER sell out to China!" (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
"We will NEVER sell out to China!" (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
"We will NEVER sell out to China!" (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
"We will NEVER sell out to China!" (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
"We will NEVER sell out to China!" (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
NYSE:PFE

Pfizer - PFE Competitors

$50.13
+0.64 (+1.29%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$49.04
$50.13
50-Day Range
$41.75
$49.57
52-Week Range
$41.44
$61.71
Volume
32.76 million shs
Average Volume
17.65 million shs
Market Capitalization
$281.40 billion
P/E Ratio
9.64
Dividend Yield
3.23%
Price Target
$56.47

PFE vs. MRK, ABBV, LLY, BMY, JNJ, ZTS, NVO, AZN, NVS, and ABT

Should you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), Zoetis (ZTS), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Novartis (NVS), and Abbott Laboratories (ABT). These companies are all part of the "pharmaceutical preparations" industry.

Pfizer vs.

Pfizer (NYSE:PFE) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk, institutional ownership and community ranking.

Pfizer received 543 more outperform votes than Merck & Co., Inc. when rated by MarketBeat users. Likewise, 70.39% of users gave Pfizer an outperform vote while only 67.06% of users gave Merck & Co., Inc. an outperform vote.

CompanyUnderperformOutperform
PfizerOutperform Votes
1457
70.39%
Underperform Votes
613
29.61%
Merck & Co., Inc.Outperform Votes
914
67.06%
Underperform Votes
449
32.94%

67.9% of Pfizer shares are owned by institutional investors. Comparatively, 73.3% of Merck & Co., Inc. shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Pfizer has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500.

Pfizer has a net margin of 29.81% compared to Merck & Co., Inc.'s net margin of 25.88%. Merck & Co., Inc.'s return on equity of 46.57% beat Pfizer's return on equity.

Company Net Margins Return on Equity Return on Assets
Pfizer 29.81% 43.95% 19.80%
Merck & Co., Inc. 25.88% 46.57% 18.24%

In the previous week, Pfizer had 2 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 12 mentions for Pfizer and 10 mentions for Merck & Co., Inc.. Merck & Co., Inc.'s average media sentiment score of 0.82 beat Pfizer's score of 0.29 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pfizer
1 Very Positive mention(s)
5 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Merck & Co., Inc.
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pfizer presently has a consensus price target of $56.47, indicating a potential upside of 12.64%. Merck & Co., Inc. has a consensus price target of $106.00, indicating a potential downside of 3.74%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Merck & Co., Inc..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pfizer
0 Sell rating(s)
9 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.36
Merck & Co., Inc.
0 Sell rating(s)
4 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.82

Pfizer pays an annual dividend of $1.60 per share and has a dividend yield of 3.2%. Merck & Co., Inc. pays an annual dividend of $2.76 per share and has a dividend yield of 2.5%. Pfizer pays out 30.8% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 45.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer is clearly the better dividend stock, given its higher yield and lower payout ratio.

Pfizer has higher revenue and earnings than Merck & Co., Inc.. Pfizer is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$81.29 billion3.46$21.98 billion$5.209.64
Merck & Co., Inc.$48.70 billion5.73$13.05 billion$6.0118.32

Summary

Pfizer beats Merck & Co., Inc. on 11 of the 21 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PFE vs. The Competition

MetricPfizerPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$277.80B$5.90B$4.68B$13.90B
Dividend Yield3.23%2.39%7.23%3.68%
P/E Ratio9.647.12138.9419.96
Price / Sales3.46399.023,216.8927.86
Price / Cash9.1321.2722.4938.92
Price / Book3.034.925.986.25
Net Income$21.98B$184.33M$163.16M$887.94M
7 Day Performance2.62%1.27%0.98%1.10%
1 Month Performance4.42%5.17%4.71%4.08%
1 Year Performance-8.32%-35.15%-28.43%-8.14%

Pfizer Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRK
Merck & Co., Inc.
2.7274 of 5 stars
$110.12
+1.2%
$106.00
-3.7%
+47.0%$279.20B$48.70B18.3268,000Dividend Increase
ABBV
AbbVie
2.6219 of 5 stars
$161.18
+1.9%
$158.56
-1.6%
+39.8%$285.04B$56.20B21.5250,000
LLY
Eli Lilly and
3.124 of 5 stars
$371.08
+2.0%
$359.78
-3.0%
+49.6%$352.59B$28.32B55.7235,000Short Interest ↓
BMY
Bristol-Myers Squibb
2.7139 of 5 stars
$80.28
+1.6%
$79.00
-1.6%
+49.7%$170.69B$46.39B26.1532,200
JNJ
Johnson & Johnson
2.5738 of 5 stars
$178.00
+1.1%
$181.33
+1.9%
+14.2%$465.38B$93.78B24.79141,700
ZTS
Zoetis
2.7172 of 5 stars
$154.14
+4.3%
$215.17
+39.6%
-30.6%$71.84B$7.78B35.1912,100
NVO
Novo Nordisk A/S
2.7011 of 5 stars
$124.60
+2.7%
$717.14
+475.6%
+16.6%$281.97B$22.40B36.9745,000Gap Up
AZN
AstraZeneca
2.6087 of 5 stars
$67.97
+2.9%
$80.67
+18.7%
+26.1%$210.63B$37.42B101.4583,100Short Interest ↓
NVS
Novartis
2.1869 of 5 stars
$89.56
+2.5%
$85.45
-4.6%
+12.4%$198.16B$51.63B9.20104,323
ABT
Abbott Laboratories
2.8693 of 5 stars
$107.58
+2.5%
$123.00
+14.3%
-14.5%$187.57B$43.08B24.28113,000Short Interest ↑
High Trading Volume
This page (NYSE:PFE) was last updated on 12/1/2022 by MarketBeat.com Staff